TCRT_OUT_1 [2025-04-04 09:47:27 -0400] 3201 Bytes | 912 tokens | Cum: 912 tkns (11.40% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 9:47:26 AM on Fri Apr 04, 2025 -0400, and I'm firing up the spotlight on Alaunos Therapeutics (TCRT), moving from 4.22 to 4.8875. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: Alaunos Therapeutics (TCRT)
IPO: 2005-08-24 (19 Years Ago)
Market Cap: $3,458,704
Shares Outstanding: 1,600,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.

Here’s the first list of news for Alaunos Therapeutics:

C1 - Oct-11-24 08:57AM - Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy
C2 - May-15-24 10:55PM - TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024
C3 - Apr-08-24 12:52PM - TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023
C4 - Dec-18-23 07:57AM - Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
C5 - Nov-14-23 07:56AM - Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?
C6 - Nov-14-23 07:56AM 07:30AM - Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
C7 - Aug-14-23 04:05PM - Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
C8 - Jun-29-23 07:00AM - Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

Prior AI Reports for TCRT:
1. 2025-04-03 – Score: 70 – Target: 5.5000 – Highs: 4.7900 / – / –
surging-sales-and-strong-performance-propel-potential-upside
2. 2025-04-02 – Score: 60 – Target: 3.2400 – Highs: 3.2150 / 4.7900 / –
company-shows-promising-growth-despite-negative-financials
3. 2025-04-01 – Score: 55 – Target: 3.3300 – Highs: 2.7500 / 3.2150 / 4.79
rising-volume-amid-financial-distress-a-paradoxical-scenario

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Alaunos Therapeutics (TCRT).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

TCRT_OUT_3 [2025-04-04 09:47:32 -0400] 1100 Bytes | 267 tokens | Cum: 1182 tkns (14.77% of 8k)
==========================================================================

Showing C1 (chunk 1 of 2): C1:
**Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy**
Date: Oct-11-24 08:57AM
Source: (TipRanks)
URL: https://finance.yahoo.com/news/alaunos-therapeutics-ends-licensing-deal-125737537.html

The latest announcement is out from Alaunos Therapeutics ((TCRT)).

Alaunos Therapeutics, Inc. has decided to terminate its amended licensing agreement with Precigen, Inc. for developing neoantigen T-cell receptors to treat solid tumor cancers, signaling a shift in strategic priorities. The original agreement, in place since 2018, will end following Alaunos’s assessment of its business goals and the impending patent expiration of the Sleeping Beauty gene transfer platform in 2026. Despite this, Alaunos is actively pursuing its intellectual property rights for certain T-cell receptors and exploring various strategic options, including mergers and partnerships, to advance its business in

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_5 [2025-04-04 09:47:35 -0400] 278 Bytes | 89 tokens | Cum: 1383 tkns (17.29% of 8k)
==========================================================================

Showing C1 (chunk 2 of 2): terests.

See more insights into TCRT stock onTipRanks’ Stock Analysis page.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_7 [2025-04-04 09:47:36 -0400] 990 Bytes | 292 tokens | Cum: 1742 tkns (21.77% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-04T10:40:20Z - North American Morning Briefing: Stock Futures Fall, Bonds Rally as Investors Negotiate Market Turmo...
A2 - 2025-04-03T17:06:22Z - 11 Health Care Stocks Moving In Thursday's Intraday Session - Aldeyra Therapeutics (NASDAQ:ALDX), Ap...
A3 - 2025-04-02T17:06:16Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Allakos (NASDAQ:ALLK), Alumis (NASDAQ...
A4 - 2025-04-01T17:05:47Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - bioAffinity Technologies (NASDAQ:BIAF),...
A5 - 2025-03-28T11:03:20Z - North American Morning Briefing: Tariff Jitters -2-...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TCRT_OUT_9 [2025-04-04 09:47:40 -0400] 1099 Bytes | 289 tokens | Cum: 2033 tkns (25.41% of 8k)
==========================================================================

Showing A1 (chunk 1 of 11): A1:
**North American Morning Briefing: Stock Futures Fall, Bonds Rally as Investors Negotiate Market Turmoil**Date: 2025-04-04Source: {'uri': 'morningstar.com', 'dataType': 'news', 'title': 'Morningstar'}URL: https://www.morningstar.com/news/dow-jones/202504042472/north-american-morning-briefing-stock-futures-fall-bonds-rally-as-investors-negotiate-market-turmoilStock futures pointed to further losses as investors continue to digest the fallout of President Trump's tariff day .

Investors ramped up bets on significant rate cuts this year, expecting action from the Federal Reserve to shore up the U.S. economy.

Benchmark Treasury yields fell below 4% for the first time since October on fears of a recession, with investors seeking safety in government bonds .

Jobs data due at 0830 ET is likely to be overshadowed by tariff fallout, CMC Markets said.

Stocks to Watch

Apple fell 0.8%, exten

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_11 [2025-04-04 09:47:48 -0400] 1099 Bytes | 279 tokens | Cum: 2430 tkns (30.38% of 8k)
==========================================================================

Showing A1 (chunk 2 of 11): ding a hit it took on Thursday due to its dependence on Chinese manufacturing. The country was taregted heavily with tariffs.

Tesla declined 1% after a 5.5% slump on Thursday.

Nvidia rose 0.3%, reboundig slightly from a 7.8% fall yesterday. Fellow chip makers Advanced Micro Devices, Qualcomm, and Broadcom were flat to lower

Dell Technologies was down 0.3% following a 19% fall on Thursday.

Intel rose 0.8% after a report that it and Taiwan Semiconductor Manufacturing reached a preliminary agreement to form a joint venture to operate Intel's chipmaking.

GameStop rose 4% after CEO Ryan Cohen increased his stake in the videogame retailer.

Affirm fell 0.7% and PayPal declined 1.2% following steep declines on Thursday.

Watch For:

Employment Report for March; Canada Labour Force Survey for March

Today's Top Headlines/Must Reads:

- A Market-Rattling Attempt to Make the American Economy

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_13 [2025-04-04 09:47:49 -0400] 1084 Bytes | 325 tokens | Cum: 2933 tkns (36.66% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-02-01T18:17:44Z - Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B2 - 2024-01-10T18:06:18Z - Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B3 - 2024-01-05T13:03:11Z - Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket
B4 - 2023-12-19T18:34:55Z - Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B5 - 2023-12-19T13:09:17Z - Why Motus GI Holdings Shares Are Trading Lower By Around 46%; Here Are 20 Stocks Moving Premarket
B6 - 2023-12-18T18:05:04Z - Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TCRT_OUT_15 [2025-04-04 09:47:57 -0400] 1098 Bytes | 311 tokens | Cum: 3246 tkns (40.58% of 8k)
==========================================================================

Showing B3 (chunk 1 of 2): B3:
**Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/01/36508372/why-dermata-therapeutics-shares-are-trading-higher-by-over-57-here-are-20-stocks-moving-premarketShares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis.
Dermata Therapeutics shares jumped 57.3% to $0.9601 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Gainers

Ainos, Inc.(NASDAQ: AIMD) gained 142.6% to $4.20 in pre-market trading after falling more than 12% on Thursday.
Safe and Green Development Corporation (NASDAQ: SGD) shares rose 34.5% to $1.83 in pre-market trading. Safe And Green Development recently

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_17 [2025-04-04 09:48:05 -0400] 766 Bytes | 224 tokens | Cum: 3590 tkns (44.88% of 8k)
==========================================================================

Showing B3 (chunk 2 of 2): issued an update on LOI for acquisition of Xene AI Software platform.
Pinstripes Holdings Inc. (NYSE: PNST) shares gained 17.4% to $6.18 in pre-market trading after dipping over 35% on Thursday.
Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) shares climbed 12.6% to $9.50 in pre-market trading. Fusion Pharmaceuticals said it has achieved alignment with the FDA on a protocol and development plan for FPI-2265.
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) shares gained 10.5% to $1.48 in pre-market trading.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares rose ...

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_19 [2025-04-04 09:48:06 -0400] 1100 Bytes | 233 tokens | Cum: 3968 tkns (49.60% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S4 - 2025-03-31 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing else...

S5 - 2025-03-31 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing else...

S6 - 2025-03-31 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing else...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TCRT_OUT_21 [2025-04-04 09:48:07 -0400] 1098 Bytes | 228 tokens | Cum: 4198 tkns (52.48% of 8k)
==========================================================================

Showing S4 (chunk 1 of 6): S4:
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results, levels of activity, performance or achievements could differ materially from those contained in or implied by any forward-looking statements. Factors that could cause or contribute to these differences include those under Risk Factors included in Part I, Item 1A and under Special Note Regarding Forward-Looking Statements or in other parts of this Annual Report on Form 10-K. All share amounts pre

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_23 [2025-04-04 09:48:13 -0400] 1098 Bytes | 265 tokens | Cum: 4465 tkns (55.81% of 8k)
==========================================================================

Showing S4 (chunk 2 of 6): sented in this Item 7 give effect to the 1-for-15 reverse stock split and the 1-for-10 second reverse stock split of our outstanding shares of common stock that occurred on January 31, 2024 and July 17, 2024, respectively.

Overview

On October 10, 2024, we announced our continued progress and evaluation of our internally developed small molecule oral obesity program. The aim of this program is to develop a drug for obesity with a differentiated profile relative to currently marketed and in development oral and injectable products. We have also operated as a clinical-stage oncology-focused cell therapy company developing adoptive TCR-T cell therapy, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. On August 14, 2023, we announced a strategic reprioritization of our business and wind down of our TCR-T Library Phase 1/2 Trial. In

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_25 [2025-04-04 09:48:20 -0400] 1098 Bytes | 258 tokens | Cum: 4847 tkns (60.59% of 8k)
==========================================================================

Showing S4 (chunk 3 of 6): connection with the reprioritization, we have reduced our workforce during the third and fourth quarters of 2023, and we continue working to reduce costs in order to extend our cash runway. We continue to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. We engaged Cantor Fitzgerald Co., or Cantor, to act as strategic advisor for this process.

We have not generated any product revenue and have incurred significant net losses in each year since our inception. For the year ended December 31, 2024, we had a net loss of $4.6 million, and as of December 31, 2024, we have incurred approximately $920.4 million of accumulated deficit since our inception in 2003. We expect to continue to incur significant operating expenditures and net losses for the foreseeable fu

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TCRT_OUT_27 [2025-04-04 09:48:33 -0400] 5277 Bytes | 1463 tokens | Cum: 6461 tkns (80.76% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-----------------------+
| Volume: 327,595 | Perf Month: 230.00% | Option/Short: No / No | Sales Y/Y TTM: 80.00% |
+---------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 430.46K | Perf Quarter: 151.27% | Short Float: 3.75% | ROE: -111.83% |
+---------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 13.87 | Index: - | Short Ratio: 0.12 | ROI: -226.85% |
+---------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 92.69 | Market Cap: 7.93M | Short Interest: 0.05M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.41 | Shs Outstand: 1.60M | Beta: -1.69 | EPS Surprise: -14.29% |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA20: 160.23% | Shs Float: 1.38M | Sales Q/Q: 300.00% | P/E: - |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA50: 185.49% | Inst Own: 4.51% | Sales past 5Y: 126.87% | Earnings: - |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA200: 83.22% | Insider Own: 13.75% | Employees: 1 | |
+---------------------+-----------------------+------------------------+-----------------------+
| Perf Week: 239.04% | Insider Trans: -1.35% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: Alaunos Therapeutics, Inc. (TCRT) by Hogue Dale Curtis Jr. (See Remarks) on 2025-03-29
- Employee Stock Option (right to buy): 3000 shares at $0 (D)

Inside Trans: Alaunos Therapeutics, Inc. (TCRT) by Lackey Melinda (Legal & Administration) on 2025-03-29
- Employee Stock Option (right to buy): 1000 shares at $0 (D)

Inside Trans: Alaunos Therapeutics, Inc. (TCRT) by Groenewald Ferdinand (VP, Finance) on 2025-03-29
- Employee Stock Option (right to buy): 3000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -1127000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 4.9133
Average Volume: 1152213.39
30-Day High: 4.9133
30-Day Low: 1.4301

[Detailed Financials: Q3 2024]
- Total Assets: $3,550,000.0
- Total Liabilities: $826,000
- Total Equity: $2,724,000.0
- Current Assets: $3,550,000.0
- Current Liabilities: $826,000

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.7

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-781,000

[Detailed Financials: Q2 2024]
- Total Assets: $4,678,000.0
- Total Liabilities: $907,000
- Total Equity: $3,771,000.0
- Current Assets: $4,678,000.0
- Current Liabilities: $907,000

[Income Statement: Q2 2024]
- Revenue: $4,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.71

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-1,681,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

TCRT_OUT_29 [2025-04-04 09:48:35 -0400] 687 Bytes | 169 tokens | Cum: 6884 tkns (86.05% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

TCRT_IN_31 [2025-04-04 09:48:36 -0400] 126 Bytes | 29 tokens | Cum: 6943 tkns (86.79% of 8k)
==========================================================================

====================================
[2025-04-04 09:48:36] # Analysis Completed
Elapsed Time: 70.18 seconds